STRATA Skin Sciences, Inc. · OTC:SSKN

STRATA Skin Sciences — Investor Presentation (May 2018)

33 slides from STRATA Skin Sciences's investor presentation, May 29, 2018

  1. Slide 1: May 2018 Investor Presentation

    May 2018 Investor Presentation

  2. Slide 2: Safe Harbor Statement

    This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking s

  3. Slide 3: STRATA Investment Highlights

    STRATA Investment Highlights Providing physicians with a platform of growth by offering reimbursable solutions for psoriasis, vitiligo and eczema and is differentiated by its leading technologies and clinical superiority as well as its value added services - DTC, insurance reimbursement advocacy and

  4. Slide 4: Product Roadmap

    Product Roadmap Commercially Available *expanded indications 2001 K003705 Ultra & Ultra Plus AL8000 Ultra2 (AL10000)V400, V700 VTRAC Lamp V7 XTRAC XLAL7000 2003 K031451* 2004 K041943 2005 K051428 2008 K073659 2012 K073659 Medical Technology Development and SAB FULL PRODUCT LIFE CYCLE FDA Regulation

  5. Slide 5: Global Installed Base - Lasers In Service

    Global Installed Base - Lasers In Service US: 887 OUS: 668 Over 1,550 Lasers Installed Worldwide* Marketed in the U.S. mainly under a recurring revenue model in which systems are placed in physicians’ offices for no upfront charge, revenues on a per-use basisMarketed OUS through distributors *As of

  6. Slide 6: Management Team

    Management Team Dr. Dolev Rafaeli President & CEO PhotoMedex, 2011-2017 & STRATA 2018 Shmuel Gov Executive VP & General Manager, PhotoMedex, 2014-2015 & STRATA 2015 - Matt Hill VP & CFO, 2018 Keith Simeone VP Sales, PhotoMedex, 2004-2015 & STRATA 2015 - Jay Sturm, Esq. General Counsel, 2015 Natalie

  7. Slide 7: People, Intellectual Property, Facilities

    People, Intellectual Property, Facilities STRATA 10-K Annual Report; Dec 31, 2017 Customer Support Call Center & Reimbursement Support Center 2015 2016 2017 Leads 36,473 21,296 7,269 Appointments 10,032 6,524 2,563 RDX charts 22,991 21,456 17,551 Facilities IP Location Primary Purpose ISO Certificat

  8. Slide 8: Disease Prevalence And Treatment Penetration

    Psoriasis Vitiligo & Leukoderma Eczema /Atopic Dermatitis Patient Population WW (% of WW population affected) 125M (2-3%) 65-95M (0.5%-2%) 580M (3% Adults, 20% children<18) Patient Population US 7.5M 1.6 - 6.5M 32M Eczema/ 18M AD # XTRAC patients treated (US, 2016 by consigned lasers) 16K 5K 929 % o

  9. Slide 9: Xtrac: Standard Of Care NB-UVB Treatment Of Psoriasis & Dermatological Conditions

    Xtrac®: Standard Of Care NB-UVB Treatment Of Psoriasis & Dermatological Conditions XTRAC excimer laser, uses a highly targeted (308nm) beam of UVB light to treat affected skin areas without damaging surrounding tissueFDA cleared for treatment of: psoriasis, vitiligo, atopic dermatitis, leukodermaPat

  10. Slide 10: Success Criteria for Good Clinical Results

    Success Criteria for Good Clinical Results Common Guidelines Patient must have at least 8 treatments in 6 weeks (“8N6”) - Consistency of recurring appointments is critical Start with a high dose Increase dose at every treatment 01 02 03

  11. Slide 11: Criteria For Optimal Clinical Outcomes: 8N6 Protocol

    Criteria For Optimal Clinical Outcomes: 8N6 Protocol 01 A few days between treatments: Minimum 8 visits in 6 weeks 02 Starting dose of at least 300 mj 03 Increase Dose over Time 04 Patient Returns: At least 8 visits per patient 05 …and management of the database to track results

  12. Slide 12: Past Performance

    Past Performance 2013 2014 2015 2016 2017 2012 Based on STRATA 10-k Annual Report; Dec 31, 2017* STRATA bought XTRAC business from PhotoMedex in 2015

  13. Slide 13: Media Spend to XTRAC Treatment Revenue

    Media Spend to XTRAC Treatment Revenue Based on STRATA and PhotoMedex Investor Presentations* STRATA bought XTRAC business from PhotoMedex in 2015

  14. Slide 14: Turnaround Strategy

    Turnaround Strategy Domestic Market OUS Markets Enhance technology offeringExpand geographical reach in certain markets Rebuild XTRAC value proposition for physician accountsDTC as a revenue driver: Online and offline advertisement, in-house call centerPractice Development Programs: Improve office p

  15. Slide 15: XTRAC DTC Advertising

    XTRAC DTC Advertisina Psoriasis Dermatologist Recommended Medicaid & Medicare Okay No Drugs oF cts FOA-Clested Virtually No Pain XTRAC Vthigo Laser Treatment - Dermatologist Recommended Ga) consulta STRATA

  16. Slide 16: Lead Generation is a Business Driver

    Lead Generation is a Business Driver Patient leads generated by DTC in a single quarter

  17. Slide 17: Social Media Reach Initial Results

    Social Media Reach Initial Results Total Likes Total Reach

  18. Slide 18: XTRAC State Of The Union (Q1 2018)

    XTRAC State Of The Union (Q1 2018) Clinical Outcomes 40% of all patients treated have a regimen that provides NO clinical resultAdding all patients to 8N6 will increase Company revenue by $5.4M annually ($7k/account) Type of patient Number of Visits on Average Comply 8+6 11 Not Comply 4 Retention Ra

  19. Slide 19: Coupons as a Promotion Tool and a Proxy For Treatment

    Coupons as a Promotion Tool and a Proxy For Treatment If all patients utilizing coupons were in the 8N6 or better, domestic revenue could increase by $5.4M ($7k/account) $40 per treatment co-pay reimbursement, max $400 in 120 days Revenue = # of lasers x # of treatments/pt x # patients x cost x recu

  20. Slide 20: Case Examples

    Case Examples Data collected directly from the lasers demonstrates the importance of following treatment guidelines Revenue = # of lasers x # of treatments/pt x # patients x cost x recurrence factor

  21. Slide 21: Optimal Therapeutic Dose (OTD)

    Optimal Therapeutic Dose (“OTD”) MECHANISMTip applies 4 simultaneous doses of energy to the patient’s plaque PURPOSETo minimize number of treatments to clearance USEDose allows provider to determine blister threshold unique to each patient and each plaque. Expected submission planned for end of Quar

  22. Slide 22: OTD Advantages in the Market

    OTD Advantages in the Market Attributes OTD Treatments Traditional Treatments Office Visits 1x / week 2x / week Treatment Weeks 4-6 6-10 Protocol Variance(#1 cause of poor results*) Dosing Standardized (no physician input required) Requires physician assessment at every visit (+/-) 0% - 25% dose Tre

  23. Slide 23: Clinical Trials

    Study 1: UCSF Dr. Tina Bhutani Study Details Metrics: mPASI & Physician Global Assessment (PGA) Endpoint: Protocol & Dose Varied Patients: 4 Study 2: Multi-Center Dr. Ben Lockshin Dr. Neal Bhatia Dr. Tina Bhutani Study Details Metrics: mPASI and Patient Response Surveys Endpoint: Percentage improvem

  24. Slide 24: Study #1 @ UCSF

    Study #1 @ UCSF Nearly 100% clear in 4 treatments After 4 tx After 2 tx Baseline

  25. Slide 25: XTRAC Revenue Growth Drivers

    XTRAC Revenue Growth Drivers Revenue = # of lasers x # of treatments/pt x # patients x cost x recurrence factor Increase number of accounts Better clinical outcomes DTC sends more patients to physicians’ offices Disease market penetration High Dose/OTD and 8N6 protocol help to retain patients for lo

  26. Slide 26: Retention, Patient Pool, DTC & Sign-up Rate

    Retention, Patient Pool, DTC & Sign-up Rate Standard Office:Low retention Standard Office: High retention “Center of Excellence” Patients per year 32 32 90 Retention rate 10% 50% 75% DTC per year 0 12 12 Avg. annual revenue $24,448 $47,200 $135,750 Growth Rate -69% 31% 39% Sign up rate 50% 50% 90% Y

  27. Slide 27: Financial Profile: Revenue And Gross Margins 2012-2017

    Financial Profile Revenue And Gross Margins 2012-2017 Revenues Gross Margins * * Based on STRATA 10K and PhotoMedex Investor Presentations* STRATA bought XTRAC business from PhotoMedex in 2015

  28. Slide 28: Financial Profile: Shares and Share Equivalents

    STRATA 10-k Annual Report; Dec 31, 2017 Financial Profile Shares and Share Equivalents 2015 2016 2017 Post Closing Common stock outstanding 2,056,679 2,166,898 4,304,425 24,894,842 Convertible debentures 9,287,025 9,221,143 - - Convertible preferred stock 507,173 467,836 13,450,636 8,600,959 Stock o

  29. Slide 29: STRATA Investment Highlights

    STRATA Investment Highlights Providing physicians with a platform of growth by offering reimbursable solutions for psoriasis, vitiligo and eczema and is differentiated by its leading technologies and clinical superiority as well as its value added services - DTC, insurance reimbursement advocacy and

  30. Slide 30: Appendix

    APPENDIX é STRATA

  31. Slide 31: Financial Profile Revenue And Gross Margins 2012-2017

    STRATA 10-k Annual Report; Dec 31, 2017 $ in Thousands 2012 2013 2014 2016 2017 Recurring Sales 8,441 15,489 22,871 28,308 23,508 22,640 Total Sales 32,226 36,406 42,610 33,601 30,707 31,449 Gross Income Recurring Sales 3,357 8,683 15,652 20,989 14,745 13,896 Gross Margin Recurring Sales 39.8% 56.1%

  32. Slide 32: MMD Tip: Case Example

    MMD Tip: Case Example CASE EXAMPLE: TEST DOSE 5000 MJ/CM2 5000 4000 3000 2000 1500 First Non-Blistering Dose = 2000 mj/cm2 Dose at 2000 mj/cm2 until scaling and induration subside

  33. Slide 33: Board of Directors

    Board of Directors Dr. Uri GeigerChairman. Co-Founder and Managing Partner of Accelmed Growth Partners. Previously CEO of Exalenz Bioscience Ltd., GalayOr Networks and founding partner of Dragon Variation Fund. David GillServed as President & Chief Financial Officer of EndoChoice Inc., and previousl

STRATA Skin Sciences — Investor Presentation (May 2018) on 6ix